Citations

Clear

17 citation(s) found for "Papadakis, Konstantinos".

AVB-114 Demonstrates Clinical Benefit in Persistent Crohn's Perianal Fistulas: Randomized Cohort Results From the Multicenter STOMP2 Trial
Schwartz, David A., Dozois, Eric J. , Ehman, Eric C. , Faubion, W, Hudesman, David, Pabla, Baldeep , Papadakis, K, Fleshner, Phillip, Dozois, Eric, Ehman, Eric , Faubion, William , Papadakis, Konstantinos , Schwartz, David A. , Hudesman, D, Johnson, Todd , Fleshner, Phillip

Mayo Clinic

American Journal of Gastroenterology | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004005 | PMID 41879234 Get It

INTRODUCTION: Advanced therapies infrequently achieve complete fistula closure in patients with Crohn's disease (CD). The primary objective of the STOMP2 clinical trial was to determine whether the implantable autologous cell therapy AVB-114 is effective in inducing remission of persistent Crohn's perianal fistulas versus standard of care. METHODS: Eligible patients had a single perianal fistula tract and had failed previous treatment or had documented medication intolerance to biologic or conventional CD therapy. All enrolled subjects underwent surgical fistula optimization and adipose tissue biopsy collection (to manufacture AVB-114) followed by 1:1 randomization to either standard of care (repeat fistula optimization including seton replacement) or AVB-114 implantation. The primary end point was combined fistula remission at 36 weeks, defined as closure of the external opening, no drainage of fluid despite gentle finger compression, and no collections >2 cm in at least 2 of the 3 dimensions on MRI. RESULTS: Subjects at 14 US sites were equally randomized to SoC (N = 24) or AVB-114 (N = 24). Week 36 combined remission was 8.3% and 45.8% for subjects randomized to SoC and AVB-114, respectively (38% difference, 95% CI 11%–60%; P = 0.0078). At week 36, MRI revealed no subjects with collections >2 cm, radiological improvement (≥50% decrease in the Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease (MAGNIFI-CD) score from baseline) in 1 SoC subject and 3 AVB-114 subjects, and radiological healing (complete resolution of T2-weighted hyperintensity in fistula tract) in 2 SoC subjects and 5 AVB-114 subjects. Through week 36, there were 40 and 56 treatment emergent adverse events for SoC and AVB-114, respectively. There were no serious treatment emergent adverse events in the AVB-114 group through week 36. DISCUSSION: A significantly higher proportion of patients treated with AVB-114 achieved combined remission vs SoC, and the treatment was well tolerated. These data support the safety and efficacy of AVB-114 in persistent Crohn's perianal fistulas.
Ustekinumab-Induced Vasculitis in a Patient With Crohn's Disease
Velasquez, Luis E. Ospina, Papadakis, Konstantinos , Urquhart, Siri A. , Ospina Velasquez, Luis E, Papadakis, Konstantinos A.

Mayo Clinic

ACG Case Reports Journal | March 5, 2025 | Volume: 12 | Issue: 3 | Pages: e01625

10.14309/crj.0000000000001625 | PMID 40046648 Get It

ABSTRACT Immunoglobulin A vasculitis (IgAV) is an immune-mediated disorder that commonly involves dermatologic, musculoskeletal, renal, and gastrointestinal systems. Drug-induced cases of IgAV are rare and sparsely documented in the literature. We report a case of a patient with Crohn's disease who developed a tender, palpable purpuric rash on the torso and extremities 3 weeks after receiving a dose of ustekinumab. This case underscores the importance of considering IgAV in patients with inflammatory bowel disease who present with cutaneous symptoms while undergoing treatment with advanced therapies.
Vulvar Crohn's Disease: Clinical Features and Outcomes
Cho, Janice , Loftus, Edward V. , Bruining, David H. , Chedid, Victor , Faubion, William A. , Johnson, Amanda M. , Kane, Sunanda V. , Papadakis, Konstantinos A. , Pardi, Darrell S. , Picco, Michael F., Raffals, Laura E. , Schroeder, Kenneth W., Tremaine, William J., Cho, Janice M, Chedid, Victor G , Loftus, Edward V , Farraye, Francis A. , Kisiel, John B. , Malik, Talha A. , Coelho–Prabhu, Nayantara

Mayo Clinic

American Journal of Gastroenterology | September 9, 2021 | Volume: 116 | Issue: 11 | Pages: 2296-2299

10.14309/ajg.0000000000001502 | PMID 34732676 Get It

INTRODUCTION: Vulvar involvement is a rare complication of Crohn's disease (CD). The optimal treatment of vulvar CD is unknown. METHODS: We conducted a 25-year retrospective cohort study of vulvar CD from 3 referral centers. Clinical features and outcomes were studied. RESULTS: Fifty patients were identified. The most common vulvar symptoms were pain (74%), edema (60%), ulcerations (46%), nodules (36%), and abscess (34%). Medical management leading to symptomatic improvement varied, and 5 patients ultimately required surgery. DISCUSSION: Vulvar CD manifests with a broad spectrum of symptoms. Aggressive medical management was frequently effective, although surgery was required in 10% of cases.
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
Ramos, Guilherme Piovezani , Al‐Bawardy, Badr , Neto, Manuel B. Braga , Bledsoe, Adam C. , Quinn, Kevin P. , Heron, Valérie , Johnson, Amanda M. , Chedid, Victor , Papadakis, Konstantinos A. , Pardi, Darrell S. , Kane, Sunanda V. , Tremaine, William J., Raffals, Laura E. , Bruining, David H. , Faubion, William A. , Harmsen, William S. , Loftus, Edward V. , Braga Neto, Manuel Bonfim, Johnson, Amanda , Chedid, Victor G , Pardi, Darrell, Kane, S , Raffals, Laura , Loftus, Edward V , Braga Neto, Manuel B , Ramos, Guilherme P , Willrich, Maria Alice V. , Coelho–Prabhu, Nayantara , Kisiel, John B.

Mayo Clinic

Crohn's & Colitis 360 | March 3, 2021 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/crocol/otab019 | PMID 36776673 Get It

Abstract Background Certolizumab pegol (CZP) has been successfully used for the treatment of Crohn disease (CD); however, real-world data regarding the utility of CZP trough levels (CTLs) are lacking. We aimed to correlate CTL with CD outcomes and to determine frequency of CZP antibodies. Methods Retrospective evaluation of all CD patients on maintenance CZP with CTL obtained between 2016 and 2019. Outcomes included: median CTL, presence of anti-CZP antibodies, biochemical response (BR), clinical response (CR), radiologic response (RR), radiologic healing (RH), and mucosal healing (MH). Results Seventy-seven CD patients were included. Median CTL was 18.9 µg/mL (interquartile range, 7.6–35.4). Twenty-three patients (27.3%) had positive antibody levels, with lower median CTL compared to patients with no antibodies (0.0 vs 29.8; P < 0.0001). Median CTL levels were higher in patients with vs without CR (30.4 vs 10.3 µg/mL; P = 0.0015) and RR (29.6 vs 5.8 µg/mL; P = 0.006). CZP dosing at least every 2 weeks was associated with higher odds of achieving MH (odds ratio, 3.2; 95% confidence interval, 1.03–9.97). CTL resulted in change in clinical management in 62.7% of cases and presence of CMZ antibodies was associated with an odds ratio of 5.83 (95% confidence interval, 1.57–21.73) of change in management. Receiver operating characteristic curve and quartile analysis suggested that CTL >19 µg/mL is associated with increased rates of CR and RR. Conclusions Higher CTL was significantly associated with CR and RR. The rate of CZP antibodies was 27.3%. Our data suggest maintenance CTL of ≥19 µg/mL should be achieved in order to optimize outcomes in clinical practice.
A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy
Bruining, David H. , Faubion, William A. , Kane, Sunanda V. , Papadakis, Konstantinos A. , Pardi, Darrell S. , Raffals, Laura E. , Schroeder, Kenneth W., Tremaine, William J., Fruth, Kristin M. , Harmsen, William S. , Loftus, Edward V. , Fruth, Kristin, Loftus, Edward V , Coelho–Prabhu, Nayantara , Kisiel, John B.

Mayo Clinic

Inflammatory Bowel Diseases | June 12, 2020 | Volume: 27 | Issue: 5 | Pages: 594-602

10.1093/ibd/izaa146 | PMID 32529198 Get It

Abstract Background We sought to compare the dysplasia detection rate of high-definition white light endoscopy (HDWLE) with that of chromoendoscopy in patients with long-standing inflammatory bowel disease (IBD). Methods This is a retrospective observational cohort of patients with IBD who underwent surveillance colonoscopy between October 1, 2016 and September 30, 2017. We assessed the association between dysplasia detection and multiple variables. Results A total of 808 unique colonoscopies were performed, of which 150 (18.6%) included chromoendoscopy. Primary sclerosing cholangitis was a comorbid diagnosis in 24.5% of patients. The performing endoscopist was an IBD specialist with 37.1% of patients and had >10 years’ experience with 64.9% of patients. Prior dysplasia had been seen in 245 (30.3%) patients: 102 (68.0%) and 143 (22.0%) among patients who had chromoendoscopy and HDWLE, respectively. Dysplasia in polyps was found in 129 procedures (15.1%). Among patients who had chromoendoscopy and HDWLE, polypoid dysplasia was identified in 50 (33.0%) and 79 (12.0%) patients, respectively, P < 0.01. Dysplasia in random biopsies was found in 39 patients (4.8%): 15 (10%) who had chromoendoscopy and 24 (3.6%) who had HDWLE (P < 0.001). On multivariate analysis, patient and disease characteristics significantly associated with an increased odds for polypoid dysplasia included older age at diagnosis (odds ratio [OR] = 1.3 per 10 years; 95% confidence interval [CI], 1.07-1.60), having an IBD physician endoscopist (OR = 1.6; 95% CI, 1.01-2.67), having an endoscopist with less than 10 years’ experience (OR = 1.8; 95% CI (1.16-2.89), and prior random dysplasia (OR = 4.2; 95% CI (1.93-9.17). Concomitant primary sclerosing cholangitis was significantly associated with random dysplasia (OR = 2.3; 95% CI, 1.02-5.07). After multivariate analysis adjusting for these variables, chromoendoscopy was no more likely to identify dysplasia than was HDWLE. Conclusions Chromoendoscopy and HDWLE had a similar diagnostic yield for dysplasia detection in patients with chronic IBD-colitis after adjusting for multiple known risk factors.
P103 Ileocecal Obstruction Secondary to Campylobacter Jejuni Ileitis
Vu, Ta , Watkins, Ryan , Hanada, Yuri , Schupack, Daniel , Chua, Heidi K, Papadakis, Konstantinos , Oblizajek, Nicholas R.

Mayo Clinic

American Journal of Gastroenterology | December 3, 2019 | Volume: 114 | Issue: 1 | Pages: S27-S27

10.14309/01.ajg.0000613380.08908.19 Get It

BACKGROUND: Acute ileitis is most classically associated with inflammatory bowel disease. However, several infections can also cause inflammation or obstruction of the terminal ileum. Clinical presentation is usually acute and characterized by abdominal pain of the right abdomen. CASE REPORT: We report the case of a healthy 24 year-old man who presented with a two month history of right lower quadrant pain, nausea and emesis after returning from a trip to South Africa. Over the subsequent two months, he had continued symptoms and an ileocecal obstruction was demonstrated both on cross-sectional imaging and on colonoscopy. A stool pathogen panel was positive for Campylobacter jejuni, and he completed an empiric three-day course of azithromycin. Endoscopic biopsies were negative for histologic features of inflammatory bowel disease. After three hospitalizations for recurrent obstruction, an ileocecal resection was performed. The resection specimen revealed marked eosinophilia within the muscularis propria and submucosal fibrosis. The patient made an uneventful recovery following his surgery. CONCLUSION: Although inflammatory bowel disease should be excluded during the workup of terminal ileitis, this case illustrates the importance of including infections and post-infectious sequelae in the differential, especially in otherwise healthy patients with recent travel history.
Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease
Park, Sang Hyoung , Kane, Sunanda V. , Papadakis, Konstantinos A. , Bruining, David H. , Faubion, William A. , Raffals, Laura E. , Pardi, Darrell S. , Tremaine, William J., Stephens, Michael C., Khanna, Sahil , Loftus, Edward V. , Loftus, Edward V , Al‐Bawardy, Badr , Aniwan, Satimai , Coelho–Prabhu, Nayantara , Kisiel, John B. , Willrich, Maria Alice V.

Mayo Clinic

Crohn's & Colitis 360 | November 26, 2019 | Volume: 1 | Issue: 3 | Pages: No page available

10.1093/crocol/otz047 Get It

Abstract Background and Aims We aimed to evaluate the relationship of serum adalimumab trough levels (ATL) with disease activity of inflammatory bowel disease (IBD) patients in a large, well-characterized referral center-based cohort. Methods We compared serum ATL between those with clinical, biochemical, or endoscopic/radiologic disease activity and those without. Results A total of 236 patients with IBD were included. Higher cutoff levels were associated with endoscopic and/or radiologic responses (cutoff value: 5.3 mcg/mL, P = 0.003) compared with improvement in C-reactive protein (cutoff value: 4.3 mcg/mL, P = 0.031). Conclusions Higher cutoff ATL was associated with endoscopic and/or radiologic response.
The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis
Bruining, David H. , Park, Sang Hyoung , Al‐Bawardy, Badr , Kane, Sunanda V. , Prabhu, Nayantara Coelho, Raffals, Laura E. , Papadakis, Konstantinos A. , Pardi, Darrell S. , Tremaine, William J., Loftus, Edward V. , Aniwan, Satimai , Al-Bawardy, Badr , Coelho Prabhu, Nayantara, Kisiel, John B. , Loftus, Edward V

Mayo Clinic

Journal of Clinical Medicine | August 5, 2019 | Volume: 8 | Issue: 8 | Pages: 1171

10.3390/jcm8081171 | PMID 31387259 Get It

Background and aims: Patient-reported outcomes (PROs) will become increasingly important as primary endpoints in future clinical trials. We aimed to evaluate the relationship between health-related quality of life (HRQoL) and the combination of patient-reported clinical symptoms (ClinPRO2) and Mayo endoscopic subscore (MES) in patients with ulcerative colitis (UC). Methods: We conducted a prospective cross-sectional study of 90 consecutive UC patients who were scheduled for sigmoidoscopy or colonoscopy. All patients completed the following questionnaires: (1) self-rated rectal bleeding and stool frequency (ClinPRO2); (2) Short Inflammatory Bowel Disease Questionnaire (SIBDQ); (3) European Quality of Life 5-Dimensions 3-Level (EQ5D3L); (4) Work Productivity and Activity Impairment questionnaire (WPAI); (5) Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F); and (6) Hospital Anxiety and Depression Scale (HADS). The endoscopic images were graded according to the MES. “No symptoms” was defined as a symptom score of 0, and “mucosal healing” was defined as MES score of 0–1. Correlations between the combined ClinPRO2 and MES with HRQoL were assessed using Spearman’s correlation coefficients. Results: The combination of the ClinPRO2 and MES was well correlated to SIBDQ (r = −0.70), EQ5D3L (r = −0.51), WPAI (r = 0.62), FACIT-F (r = −0.58), and HADS-depression (r = 0.45). SIBDQ scores had strong correlations with FACIT-F (r = 0.86), WPAI (r = −0.80), and HADS-depression (r = −0.75) (p < 0.05 for all correlations). Patients with no symptoms reported the greatest all HRQoL scores. Conclusions: In patients with ulcerative colitis, the combination of a ClinPRO2 and the MES had good correlation with the SIBDQ. In addition, SIBDQ was well correlated to the various HRQoL.
Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al‐Bawardy, Badr , Ramos, Guilherme Piovezani , Jenkins, Sarah M. , Park, Sang Hyoung , Schoenoff, Shayla, Bruining, David H. , Papadakis, Konstantinos A. , Raffals, Laura E. , Tremaine, William J., Loftus, Edward V. , Aniwan, Satimai , Schoenoff, Shayla A, Raffals, Laura, Loftus, Edward V , Ramos, Guilherme P , Willrich, Maria Alice V.

Mayo Clinic

Inflammatory Bowel Diseases | August 24, 2018 | Volume: 25 | Issue: 3 | Pages: 580-586

10.1093/ibd/izy272 | PMID 30165638 Get It